Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects

Trial Profile

A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esketamine (Primary) ; Mirtazapine
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Acronyms DRiVESaFe
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 29 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
    • 23 Oct 2014 Planned initiation date changed from 1 Aug 2014 to 1 Sep 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top